The Wegovy Age Range: What the UK Licence Actually Says

The myth: 'Wegovy is just for younger adults or only for the very obese'

This one circulates a lot online. Some people assume Wegovy is aimed at younger patients because it appears frequently in weight-loss conversations directed at that demographic. Others assume it is reserved for people with a very high BMI. Neither is accurate. The UK licence sets a lower BMI boundary, not an upper one, and it sets a minimum age of 18 with no published maximum. What it does not do is guarantee access to everyone who clears those numbers. A GPhC-registered prescriber will look at your current medications, your health history, and any conditions that might make treatment unsuitable before a prescription is issued. Age shapes that conversation but does not close it off at either end.

The NHS semaglutide page confirms the 18-and-over minimum, and the same page explains the weight thresholds that sit alongside it. Worth a read before any consultation.

What the UK licence actually sets out for adults

The licence for Wegovy (semaglutide 2.4mg) covers adults with a BMI of 30 kg/m² or above. It also covers adults with a BMI between 27 and 29.9 kg/m² who have at least one weight-related condition: that could be high blood pressure, type 2 diabetes, high cholesterol, obstructive sleep apnoea, or a similar condition that treatment is likely to benefit. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance, typically 2.5 kg/m² below the standard figures, so a prescriber will factor in your background when reviewing your case.

The quick check you can do in under a minute: use the NHS BMI calculator to confirm your current BMI before your consultation. It will not tell you whether you are suitable (only a clinician can do that) but it saves time and gives you a clear figure to work with.

For a fuller picture of who this treatment is designed for, our overview of semaglutide for weight management covers the wider eligibility landscape. Those considering a switch from another GLP-1 medicine may also find the guidance on switching to Wegovy useful at this stage.

Older adults: no cut-off, but the assessment matters more

There is no age ceiling in the Wegovy licence. Adults in their 60s, 70s and beyond are not automatically excluded, and some may have the strongest clinical reasons to address excess weight given the associated risks to heart health and mobility. What changes with age is the complexity of the assessment. Older patients are more likely to be taking other medications, more likely to have conditions that affect kidney function, and may be at higher risk from the gastrointestinal side effects that sometimes accompany the early weeks of treatment. A prescriber will look at all of this. Frailty and muscle loss are also worth raising: the weight-loss treatment guidance covers why adequate protein and resistance activity matter alongside any medical treatment. None of this means treatment is ruled out, it means the consultation deserves to be thorough.

NICE's appraisal of semaglutide for weight management, NICE TA875, sets out the population for whom NICE recommends the treatment within NHS specialist services, and age is not one of the restricting criteria there either.

Under-18s, pregnancy and situations where age intersects with the licence

Wegovy is not licensed for anyone under 18 in the UK. This is a firm regulatory boundary, not a clinical preference, and it applies regardless of BMI or health conditions. A prescriber working within the law cannot issue a Wegovy prescription for a minor.

Pregnancy and breastfeeding sit outside the licence too. The current guidance advises that semaglutide should not be used during pregnancy, while breastfeeding, or in the period when someone is actively trying to conceive. The MHRA recommends using effective contraception during treatment, and for tirzepatide specifically there are additional notes about how oral contraceptives may be absorbed differently in the early weeks, though that applies to Mounjaro rather than Wegovy. If your circumstances in this area are changing, that is exactly the kind of thing to raise openly in a consultation.

People with questions about how age or life stage interacts with their eligibility will find more detail on our pages covering the minimum age for Wegovy and the related question of age and Wegovy eligibility more broadly. If cost is also on your mind while weighing your options, our page on Wegovy pricing in the UK explains what private treatment typically involves without any obligation to proceed.

At the end of the consultation, our prescribers review the full picture, not just age and BMI. That is the point at which a genuinely personalised decision gets made.